BlackRock Inc. boosted its holdings in Savara Inc (NASDAQ:SVRA) by 642.4% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 499,512 shares of the company’s stock after acquiring an additional 432,225 shares during the period. BlackRock Inc. owned 1.64% of Savara worth $7,412,000 as of its most recent filing with the Securities and Exchange Commission.

SVRA has been the topic of a number of research analyst reports. BidaskClub upgraded Savara from a “strong sell” rating to a “sell” rating in a research note on Thursday, April 12th. ValuEngine upgraded Savara from a “strong sell” rating to a “sell” rating in a research note on Wednesday, February 14th. Canaccord Genuity set a $25.00 price objective on Savara and gave the company a “buy” rating in a report on Monday, April 9th. Finally, Ladenburg Thalmann initiated coverage on Savara in a report on Wednesday, January 3rd. They issued a “buy” rating and a $35.00 price objective on the stock. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $23.58.

In other Savara news, CFO David L. Lowrance sold 7,000 shares of the company’s stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $12.88, for a total value of $90,160.00. Following the transaction, the chief financial officer now directly owns 33,994 shares of the company’s stock, valued at approximately $437,842.72. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Jaakko Taneli Jouhikainen sold 25,000 shares of the company’s stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $12.85, for a total value of $321,250.00. Following the completion of the transaction, the insider now directly owns 219,216 shares in the company, valued at $2,816,925.60. The disclosure for this sale can be found here. Corporate insiders own 6.93% of the company’s stock.

Shares of NASDAQ SVRA opened at $9.02 on Friday. The company has a current ratio of 16.28, a quick ratio of 16.28 and a debt-to-equity ratio of 0.13. Savara Inc has a one year low of $4.60 and a one year high of $17.19. The firm has a market capitalization of $264.12, a price-to-earnings ratio of -5.13 and a beta of 0.04.

Savara (NASDAQ:SVRA) last issued its quarterly earnings data on Wednesday, March 14th. The company reported ($0.23) EPS for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.02. equities analysts forecast that Savara Inc will post -1.43 earnings per share for the current fiscal year.

Savara Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.

Institutional Ownership by Quarter for Savara (NASDAQ:SVRA)

Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.